Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1310072

registered interest
date	19/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the rate of positive swab tests for covid-19 among people who have received both doses of a vaccination.
tabling member constituency	Altrincham and Sale West
tabling member printed	Sir Graham Brady
uin	183067
answer	answer is ministerial correction date of answer 22/04/2021 answer text <p>Data on effectiveness of two doses of COVID-19 vaccine will be published in due course, once larger numbers of the population have been vaccinated with two doses and sufficient time has elapsed for an effect to be monitored.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/04/2021 15:25:17 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	435 label Biography information for Sir Graham Brady

1310074

registered interest
date	19/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what account his Department is taking of the prevalence of false positive results when assessing the efficacy of covid-19 vaccines.
tabling member constituency	Altrincham and Sale West
tabling member printed	Sir Graham Brady
uin	183069
answer	answer is ministerial correction date of answer 22/04/2021 answer text <p>Public Health England (PHE) is considering the impact of false positives on vaccine efficacy estimates, as part of its vaccine monitoring work. Several vaccine effectiveness studies, including PHE’s, use both repeat virology swabs and antibody testing to help exclude false positives.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/04/2021 15:27:50 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	435 label Biography information for Sir Graham Brady

1309776

registered interest
date	16/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people have received a covid-19 vaccination in Bromsgrove constituency on the most recent date for which information is available.
tabling member constituency	Bromsgrove
tabling member printed	Sajid Javid
uin	182035
answer	answer is ministerial correction date of answer 22/04/2021 answer text <p>On 15 April 2021 NHS England and Improvement published data showing that between 8 December 2020 and 11 April 2021, 56,146 people in Bromsgrove had received at least one dose of a COVID-19 vaccine. This data is published at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/</a></p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/04/2021 15:22:53 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	3945 label Biography information for Sir Sajid Javid

1309797

registered interest
date	16/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 March 2019 to Question 166586 on Coronavirus: Vaccination, since the Joint Committee on Vaccination and Immunisation advised that local teams should consider a universal offer to adults experiencing homelessness and rough sleeping alongside people in priority group six, how many homeless people in the UK have received a covid-19 vaccine.
tabling member constituency	Stockport
tabling member printed	Navendu Mishra
uin	182107
answer	answer is ministerial correction date of answer 26/04/2021 answer text <p>Data is not available in the format requested.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/04/2021 15:51:44 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4811 label Biography information for Navendu Mishra

1309476

registered interest
date	15/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to (a) the definition of severe asthma set out in paragraph 1.2 of the NICE 2020 publication, COVID-19 rapid guideline: severe asthma and (b) the article by Bloom et al published in The Lancet on 4 March 2021, what assessment his Department has made of the potential merits of prioritising all asthmatics in (i) phase 2 and (ii) future phases including booster shots of the covid-19 vaccine rollout; and whether the JCVI considered the NICE guidelines on covid-19 and severe asthma when setting out the approach to covid-19 vaccination roll out in the UK.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	181447
answer	answer is ministerial correction date of answer 26/04/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) considered data from OpenSAFELY and QCOVID in determining the risk of COVID-19 in those with asthma and in determining which individuals with asthma were at significant risk of mortality from COVID-19 in phase one of the COVID-19 vaccination programme. The JCVI concluded that only a subset of those with asthma are at clinically higher risk from COVID-19. This group is defined by data from OpenSAFELY and QCOVID as adults with asthma who require continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission. The National Institute for Health and Care Excellence’s guideline Bloom et al were not used.</p><p>For phase two, the JCVI concluded that there is good evidence that the risks of hospitalisation and critical care admission from COVID-19 increase with age. The JCVI advised that the offer of vaccination during phase two is age-based starting with the oldest adults first. The JCVI has not advised prioritisation of any sub-groups and is currently considering the need for and timing of future phases and booster doses of COVID-19 vaccines. Their advice will be published in due course.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/04/2021 16:06:02 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 98078 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4784 label Biography information for Duncan Baker

1309527

registered interest
date	15/04/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccination: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps the Department is taking to support British domestic capacity to produce future vaccines.
tabling member constituency	Morley and Outwood
tabling member printed	Andrea Jenkyns
uin	181349
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>The Government has invested over £300 million to secure and scale-up the UK’s manufacturing capabilities to be able to respond to this pandemic, as well as any future pandemics. This includes:</p><p>a) Facilities that have come online:</p><ul><li>£65.5 million for the early manufacture of the University of Oxford/AstraZeneca vaccine;</li><li>£8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire;</li><li>£8.6 million to the Centre of Process Innovation to develop GMP-ready mRNA manufacturing capability;</li><li>£4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres; and</li><li>Funding for fill and finish through a contract with Wockhardt in Wrexham, North Wales, which is currently providing fill and finish capabilities to the University of Oxford/AstraZeneca vaccine.</li></ul><p>b) Facilities that will come online later this year, to help provide longer-term UK capacity:</p><ul><li>£140.6 million to accelerate the completion and expanded role of the Vaccines Manufacturing Innovation Centre in Oxfordshire;</li><li>£127 million for the Cell and Gene Therapy Catapult in Braintree, Essex; and</li><li>Funding for the expansion of the Valneva factory in Livingston, Scotland.</li></ul> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 23/04/2021 13:42:47 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4490 label Biography information for Dame Andrea Jenkyns

1308990

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that all GPs are aware of the update to JCVI guidance on prioritisation of adults for the covid-19 living with immunocompromised clinically extremely vulnerable people.
tabling member constituency	Nottingham North
tabling member printed	Alex Norris
uin	181092
answer	answer is ministerial correction date of answer 22/04/2021 answer text <p>The National Health Service has written to all general practitioner practices setting out how vaccines will be offered to this group and how eligible individuals are to be identified. A separate ‘Operational Guide’ has been created setting out more details and how the NHS plans to maximise uptake in this group. The NHS has also written to all Medical Directors setting out the steps needed to identify immunosuppressed individuals in secondary care.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/04/2021 09:17:06 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 97235 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4641 label Biography information for Alex Norris

1309125

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many doses of flucelvax have been procured for winter 2021-22.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	181042
answer	answer is ministerial correction date of answer 27/04/2021 answer text <p>Local providers are responsible for the procurement of flu vaccines. The Department has not procured any adult flu vaccines for a central stock for the upcoming winter. Information with regard to the amount of flucelvax which has been procured locally is commercially sensitive.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 27/04/2021 15:25:38 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4418 label Biography information for Justin Madders

1308454

registered interest
date	13/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether certain variants of covid-19 are less susceptible to vaccines.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	180499
answer	answer is ministerial correction date of answer 20/04/2021 answer text <p>All currently deployed COVID-19 vaccines in the United Kingdom are effective against the prevalent strains in the country.</p><p>Public Health England has published early estimates of vaccine effectiveness which includes the United Kingdom variant of concern VOC202012/01 and has shown no substantial change in vaccine effectiveness against this variant, which is now the dominant strain of COVID-19 in the UK. If other emerging variants do reduce vaccine efficacy, it would still be anticipated that the vaccines currently in deployment would continue to provide protection to some extent.</p><p>The Government are already taking several steps to understand the efficacy of the current UK vaccine portfolio against new and emerging virus variants. This includes a partnership with CureVac to develop a variation of an existing vaccine tailored to the most appropriate variant target.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 20/04/2021 15:31:12 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4131 label Biography information for Jim Shannon

1308569

registered interest
date	13/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of using a different covid-19 vaccine to Oxford-AstraZeneca for under 30 year olds who have already had their first dose of that vaccine.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	180615
answer	answer is ministerial correction date of answer 21/04/2021 answer text <p>There is currently no trial data available on the immune responses to mixed COVID-19 vaccine schedules. Such data are being developed by the National Immunisation Schedule Evaluation Consortium and will be considered by the Joint Committee on Vaccination and Immunisation (JCVI) when available. The JCVI advises that all those who have received a first dose of the Oxford/AstraZeneca COVID-19 vaccine should continue to be offered a second dose of that vaccine, irrespective of age. The second dose will be important for longer lasting protection against COVID-19. The JCVI’s statement on the use of the Oxford/AstraZeneca vaccine is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine-7-april-2021" target="_blank">https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine-7-april-2021</a></p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 21/04/2021 10:05:30 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 97263 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4776 label Biography information for Munira Wilson